GlobeNewswire Inc | Jul 20, 2020 08:30AM EDT

July 20, 2020

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Conference Call & WebcastThursday, August 6th @ 1:30 PM Pacific Time (4:30 PM Eastern Time)Domestic: 877-705-6003 (Domestic)

International: 201-493-6725

Conference ID: 13705182

The call will also be webcast and can be accessed from the Investors section of the Companys website at www.pfenex.comor http://public.viavid.com/index.php?id=140248.

A replay of the call will also be available through August 13th. Participants may access the replay from the Investors section of the Companys website at www.pfenex.com or http://public.viavid.com/index.php?id=140248.

About Pfenex Inc.

Pfenex is a development and licensing biotechnology company with commercial products focused on leveraging its proprietary protein production platform, Pfenex Expression Technology, to develop next generation and novel protein therapeutics to meaningfully improve existing therapies and create novel therapies for some of the biological targets linked to critical diseases still waiting to successfully be addressed. Using the patented Pfenex Expression Technology platform, Pfenex has created a broad pipeline that is diversified across multiple assets, including U.S. Food and Drug Administration (FDA) approved, next generation and novel biopharmaceutical products. Pfenexs lead product is Teriparatide Injection (previously referred to as PF708 and Bonsity), a therapeutic equivalent candidate to Forteo (teriparatide injection). Teriparatide Injection has been commercialized in the U.S. for, among other uses, the treatment of osteoporosis in certain patients at high risk for fracture, and marketing authorization applications are pending in other jurisdictions. In addition, Pfenex is developing hematologic oncology products in collaboration with Jazz Pharmaceuticals, including PF743, a recombinant Erwinia asparaginase, and PF745, a half-life extended recombinant Erwinia asparaginase. Pfenex also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein for use in prophylactic and therapeutic vaccines.

Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website ( http://www.pfenex.com/), its investor relations website ( http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account ( https://twitter.com/pfenex), Facebook page ( https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page ( https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD. Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Company Contact:InvestorRelations@pfenex.com